The relentless progression of chronic myeloid leukemia (CML) to blast crisis remains a major clinical challenge, characterized by resistance to standard tyrosine kinase inhibitors (TKIs) and poor survival outcomes. While BCR-ABL1 kinase activity drives early leukemogenesis, disease advancement involves complex molecular adaptations, including enhanced survival signaling through anti-apoptotic proteins like Bcl-xL. Although Bcl-xL is often overexpressed in CML-BC, its precise role in disease progression and potential as a therapeutic target have been difficult to define due to compensatory mechanisms and microenvironmental protection.
To clarify the functional significance of Bcl-xL, researchers employed an inducible mouse model where bcl-x was deleted specifically in BCR-ABL1-expressing hematopoietic stem and progenitor cells. These animals developed a chronic-phase-like myeloproliferative disorder indistinguishable from controls, demonstrating that Bcl-xL is not required for initial leukemic development or maintenance. However, none of the bcl-x-deficient mice progressed to blast crisis, indicating that Bcl-xL is essential for the survival of early progenitors undergoing transformation into aggressive, blast-like phenotypes.
This finding prompted the investigation of pharmacologic strategies targeting Bcl-xL. The BH3 mimetic ABT-263, which inhibits both Bcl-xL and Bcl-2, was tested alone and in combination with PP242—a potent dual inhibitor of mTORC1 and mTORC2.CEACAM6 Antibody Technical Information While ABT-263 alone showed minimal cytotoxicity in CML-BC cell lines and primary CD34+ progenitors, combining it with suboptimal doses of PP242 resulted in robust and selective apoptosis, affecting up to 90% of leukemic cells.Kirrothricin Formula Notably, this effect was absent in CD34+ progenitors from healthy donors, highlighting the therapeutic window of this strategy.
Mechanistically, PP242 activates BAD by suppressing Akt/mTORC1/2 signaling, leading to dephosphorylation and release of BAD from 14-3-3 complexes. Activated BAD then binds and neutralizes Bcl-xL, triggering mitochondrial outer membrane permeabilization and caspase activation. When BAD expression was silenced using shRNA, the synergistic pro-apoptotic effect of ABT-263 and PP242 was significantly diminished, confirming that BAD activation is a key mediator of this response.PMID:35185331
Furthermore, the combination effectively overcame stromal-induced drug resistance. In cultures exposed to conditioned medium from human mesenchymal stem cells—known to confer protection against TKIs—ABT-263 and PP242 induced near-complete cell death in Ph+ LAMA84 cells, even when imatinib failed. This demonstrates that targeting the Bcl-xL/BAD axis can bypass extrinsic survival signals derived from the bone marrow niche.
Additional studies revealed that suppression of hnRNP A1, a post-transcriptional regulator of Bcl-xL, downregulated Bcl-xL levels without affecting Bcl-2, mimicking the effects of ABT-263. This further confirms that Bcl-xL, rather than Bcl-2, is the critical target in CML-BC progenitors.
In summary, the ABT-263/PP242 combination represents a highly effective and selective strategy for eliminating CML-BC progenitors. By simultaneously disabling Bcl-xL and reactivating BAD, this approach induces profound apoptosis even in the presence of protective microenvironmental signals. It offers a promising alternative for patients with advanced, TKI-resistant CML, potentially paving the way for novel treatment protocols that combine TKIs with targeted apoptosis induction to achieve deeper remissions and prevent relapse.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com